Clinical Trial Update: A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial is evaluating BNT113 in combination with pembrolizumab versus pembrolizumab alone for HPV16-positive, PD-L1-expressing head and neck …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• BNT113
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: BioNTech SE | Conditions: Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer | Phase 2, Phase 3 | Status: RECRUITING